Table 4 Other inhibitors in clinical trials
From: RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Type of inhibitor | Phase | Inhibitor | Trial details | Tumor type and No. of patients | Reported data |
|---|---|---|---|---|---|
KRASG12D | 1/2 | MRTX1133 (Mirati Therapeutics) (OFF state inhibitor) | NCT05737706 | No data | No data |
1 | RMC-9805 (Revolution Medicines) (ON state, tri-complex inhibitor) | NCT06040541 | No data | No data | |
1 | HRS-4642 (Jiangsu HengRui Medicine) (Unknown) | NCT05533463 | NSCLC (n = 10); other solid tumors (n = 8) (12) | NSCLC ORR: 10% Other solid tumors ORR: 0% | |
1 | ASP3082 (Astellas) (PROTAC) | NCT05382559 | No data | No data | |
Pan-RAS/ RAS wild-type inhibitor | 1 | RMC-6236 (Revolution Medicines) (ON state; tri-complex inhibitor inhibitor) | NCT05379985 | NSCLC (n = 40); PDAC (n = 46) (12) | NSCLC ORR: 38% PDAC ORR: 20% |
Pan-RAS inhibitor | 1 | BI-3,706,674 (OFF state inhibitor) | NCT06056024 | No data | No data |
Immune therapies | 1/2 | ELI-002 7P (AMPLIFY-7P) (Elicio Therapeutics) (KRASG12D/G12R/G12V/G12A/G12C/G12S/G13D peptide vaccine + immune-stimulatory oligonucleotide) | NCT05726864 | Adjuvant treatment biomarker reduction PDAC/CRC (n = 19); Clearance of minimal residual disease (n = 4); Polyfunctional mKRAS-specific T cell responses (n = 15) (142) | PDAC/CRC–adjuvant treatment Biomarker reduction: 79% (15/19) Clearance of minimal residual disease 21% (4/19) Polyfunctional mKRAS-specific T cell responses 80% (12/15) |
1 | KRAS peptide vaccine (KRASG12D/G12R/G12V/G12A/G12C/G13D 21-mer peptide vaccine + poly-ICLC + ipilimumab/ nivolumab) | NCT05013216 | Adjuvant treatment positive (n = 11); mKRAS-specific T cell response (n = 11) (12) | mKRAS-specific T cell response: 73% ( 8/11) | |
1 | Anti-RASG12D mTCR Gilead (ex Kite)/ NCI (KRAS/HRAS/NRAS G12D; HLA-A*11:01-restricted KRAS/ HRAS/NRASG12D TCR) | NCT03745326 | No data | No data |